2018JQ8053; No.2017KJXX-70), Technology and Research Plan of Xian, China (offer No. at 12 months, usage of angiotensin changing enzyme inhibitor or angiotensin receptor blocker generally, revascularization at baseline. Furthermore, in accordance with the no therapy group, the statin monotherapy group as well as the cotherapy group demonstrated a lower threat of ischemia-driven revascularization and cardiac function NYHA III or IV development. There have been no cardiovascular fatalities, 8 MIs, and 14 strokes through the follow-up. The occurrence of cardiovascular loss of life, MI, and stroke was low and didn’t allow for additional analysis (Supplementary Desks 3, 4). Subgroup evaluation We conducted a subgroup evaluation between groupings also. In the univariate Cox regression model (Model 1), the cotherapy group demonstrated a lesser MACE incident compared to the beta-blocker monotherapy group (HR 0.39, 95% CI 0.20C0.76, Cotherapy*Cotherapy**beliefs derive from evaluation with beta-blocker monotherapy group; beliefs and **HR derive from evaluation with statin monotherapy group; aModel 1: Unadjusted; bModel 2: Multivariate modification was designed for age group, sex, cigarette smoking, body mass index; cModel 3: Multivariate modification was designed for age group, sex, smoking cigarettes, body mass index, diabetes, hypertension, previous myocardial infarction, atrial fibrillation; dModel 4: Multivariate modification was designed for age group, sex, cigarette smoking, body mass index, diabetes, hypertension, previous myocardial infarction, atrial fibrillation, use of aspirin always, usage of clopidogrel at 12 months, always utilize of angiotensin changing enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline. Furthermore, in accordance with the statin monotherapy group, the cotherapy group demonstrated a substantial 49% decrease in MACE incident (HR 0.51, 95% CI 0.28C0.92, worth /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=636 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=277 /th /thead MACE98 (15.4)40 (28.8)14 (19.7)22 (14.8)22 (7.9) 0.001?Cardiovascular death, n (%)0 (0)0 (0)0 (0)0 (0)0 (0)C?Myocardial infarction, n (%)8 (1.3)1 (0.7)2 (2.8)1 (0.7)4 (1.4)0.531?Ischemia-driven revascularization*, n (%)73 (11.5)31 (22.3)9 (12.7)16 (10.7)17 (6.1) 0.001?Improvement to NYHA IV or III, n (%)17 (2.7)7 (5.0)5 (7.0)2 (1.3)3 (1.1)0.008?Heart stroke, n (%)14 (2.2)6 (4.3)0 (0)5 (3.4)3 (1.1)0.071 Open up in another window *Included percutaneous coronary intervention and coronary artery bypass grafting. MACE C main adverse cardiac occasions; NYHA C NY Center Association. Supplementary Desk 3 Multivariate COX evaluation of ischemia-driven revascularization regarding to risk group of generally beta-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”middle” colspan=”1″ Ischemia-driven revascularization# /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.000.55 (0.26C1.15)0.48 (0.26C0.87)0.26 (0.14C0.47)? em P /em * worth0.1140.016 0.001Model 2b?HR* (95% CI)1.000.56 (0.26C1.18)0.48 (0.26C0.88)0.26 (0.15C0.48)? em P /em * worth0.1280.017 0.001Model 3c?HR* (95% CI)1.000.55 (0.26C1.16)0.45 (0.24C0.83)0.25 (0.14C0.46)? em P /em * worth0.1150.010 0.001Model 4d?HR* (95% CI)1.000.46 (0.22C0.99)0.29 (0.15C0.54)0.14 (0.08C0.26)? em P /em * worth0.047 0.001 0.001 Open up in another window *Compared using the no therapy group; aModel 1: Unadjusted; bModel 2: Multivariate modification was designed for age group, sex, cigarette smoking, body mass index; cModel F2r 3: Multivariate modification was designed for age group, sex, smoking cigarettes, body mass index, diabetes, hypertension, previous myocardial infarction, atrial fibrillation; dModel 4: Multivariate modification was designed for age group, sex, cigarette smoking, body mass index, diabetes, hypertension, previous myocardial infarction, atrial fibrillation, always utilize of aspirin, usage of clopidogrel at 12 months, always utilize of ARB or ACEI, revascularization at baseline; #included percutaneous coronary involvement and coronary artery bypass grafting. There have been 0 cardiovascular loss of life, 8 myocardial infarction, and 14 heart stroke through the follow-up. The occurrence of cardiovascular loss of life, myocardial infarction, and stroke were did and low not enable additional analysis. CI C self-confidence period; HR C threat ratio. Supplementary Desk 4 Multivariate COX evaluation of improvement to NYHA III or IV regarding to risk group of generally b-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”middle” colspan=”1″ Improvement to NYHA III or IV /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”middle” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.001.36 (0.43C4.30)0.26 (0.06C1.27)0.21 (0.05C0.80)? em P /em * worth0.5980.0970.023Model 2b?HR* (95% CI)1.001.18 (0.37C3.77)0.25 (0.05C1.21)0.20 (0.05C0.76)? em P /em * worth0.7850.0850.018Model 3c?HR* (95% CI)1.001.05 (0.32C3.38)0.24 (0.05C1.18)0.17 (0.04C0.65)? em P /em * worth0.9420.0800.010Model 4d?HR* (95% CI)1.001.04 (0.32C3.38)0.24 (0.05C1.23)0.17 (0.04C0.68)? em P /em * worth0.9520.0880.013 Open up in another window *Compared with.The incidence of cardiovascular death, myocardial infarction, and stroke were low and didn’t enable further analysis. fibrillation, always utilize of aspirin, usage of clopidogrel at 12 months, always utilize of angiotensin changing enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline. Furthermore, in accordance with the no therapy group, the statin monotherapy group as well as the cotherapy group demonstrated a lower threat of ischemia-driven revascularization and cardiac function NYHA III or IV development. There have been no cardiovascular fatalities, 8 MIs, and 14 strokes through the follow-up. The occurrence of cardiovascular loss of life, MI, and stroke was low and didn’t allow for additional analysis (Supplementary Desks 3, 4). Subgroup evaluation We conducted a subgroup evaluation between groupings also. In the univariate Cox regression model (Model 1), the cotherapy group demonstrated a lesser MACE incident Ralinepag compared to the beta-blocker monotherapy group (HR 0.39, 95% CI 0.20C0.76, Cotherapy*Cotherapy**beliefs derive from evaluation with beta-blocker monotherapy group; **HR and beliefs derive from evaluation with statin monotherapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, aged myocardial infarction, atrial fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, aged myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of angiotensin transforming enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline. In addition, relative to the statin monotherapy group, the cotherapy group showed a significant 49% reduction in MACE occurrence (HR 0.51, 95% CI 0.28C0.92, value /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=636 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead MACE98 (15.4)40 (28.8)14 (19.7)22 (14.8)22 (7.9) 0.001?Cardiovascular death, n (%)0 (0)0 (0)0 (0)0 (0)0 (0)C?Myocardial infarction, n Ralinepag (%)8 (1.3)1 (0.7)2 (2.8)1 (0.7)4 (1.4)0.531?Ischemia-driven revascularization*, n (%)73 (11.5)31 (22.3)9 (12.7)16 (10.7)17 (6.1) 0.001?Progress to NYHA III or IV, n (%)17 (2.7)7 (5.0)5 (7.0)2 (1.3)3 (1.1)0.008?Stroke, n (%)14 (2.2)6 (4.3)0 (0)5 (3.4)3 (1.1)0.071 Open in a separate window *Included percutaneous coronary intervention and coronary artery bypass grafting. MACE C major adverse cardiac events; NYHA C New York Heart Association. Supplementary Table 3 Multivariate COX analysis of ischemia-driven revascularization according to risk category of usually beta-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”center” colspan=”1″ Ischemia-driven revascularization# /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.000.55 (0.26C1.15)0.48 (0.26C0.87)0.26 (0.14C0.47)? em P /em * value0.1140.016 0.001Model 2b?HR* (95% CI)1.000.56 (0.26C1.18)0.48 (0.26C0.88)0.26 (0.15C0.48)? em P /em * value0.1280.017 0.001Model 3c?HR* (95% CI)1.000.55 (0.26C1.16)0.45 (0.24C0.83)0.25 (0.14C0.46)? em P /em * value0.1150.010 0.001Model 4d?HR* (95% CI)1.000.46 (0.22C0.99)0.29 (0.15C0.54)0.14 (0.08C0.26)? em P /em * value0.047 0.001 0.001 Open in a separate window *Compared with the no therapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, aged myocardial infarction, atrial fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, aged myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of ACEI or ARB, revascularization at baseline; #included percutaneous coronary intervention and coronary artery bypass grafting. There were 0 cardiovascular death, 8 myocardial infarction, and 14 stroke during the follow-up. The incidence of cardiovascular death, myocardial infarction, and stroke were low and did not allow for further analysis. CI C confidence interval; HR C hazard ratio. Supplementary Table 4 Multivariate COX analysis of progress to NYHA III or IV according to risk category of usually b-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”center” colspan=”1″ Progress to NYHA III or IV /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.001.36 (0.43C4.30)0.26 (0.06C1.27)0.21 (0.05C0.80)? em P /em * value0.5980.0970.023Model 2b?HR* (95% CI)1.001.18 (0.37C3.77)0.25 (0.05C1.21)0.20 (0.05C0.76)? em P /em * value0.7850.0850.018Model 3c?HR* (95% CI)1.001.05 (0.32C3.38)0.24 (0.05C1.18)0.17 (0.04C0.65)? em P /em * value0.9420.0800.010Model 4d?HR* (95% CI)1.001.04 (0.32C3.38)0.24 (0.05C1.23)0.17 (0.04C0.68)? em P /em * value0.9520.0880.013 Open in a separate window *Compared with the no therapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for.There were no cardiovascular deaths, 8 MIs, and 14 strokes during the follow-up. the follow-up. The incidence of cardiovascular death, MI, and stroke was low and did not allow for further analysis (Supplementary Furniture 3, 4). Subgroup analysis We also conducted a subgroup analysis between groups. In the univariate Cox regression model (Model 1), the cotherapy group showed a lower MACE occurrence than the beta-blocker monotherapy group (HR 0.39, 95% CI 0.20C0.76, Cotherapy*Cotherapy**values are based on comparison with beta-blocker monotherapy group; **HR and values are based on comparison with statin monotherapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, aged myocardial infarction, atrial fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, aged myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline. In addition, relative to the statin monotherapy group, the cotherapy group showed a significant 49% reduction in MACE occurrence (HR 0.51, 95% CI 0.28C0.92, value /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Ralinepag n=636 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead MACE98 (15.4)40 (28.8)14 (19.7)22 (14.8)22 (7.9) 0.001?Cardiovascular death, n (%)0 (0)0 (0)0 (0)0 (0)0 (0)C?Myocardial infarction, n (%)8 (1.3)1 (0.7)2 (2.8)1 (0.7)4 (1.4)0.531?Ischemia-driven revascularization*, n (%)73 (11.5)31 (22.3)9 (12.7)16 (10.7)17 (6.1) 0.001?Progress to NYHA III or IV, n (%)17 (2.7)7 (5.0)5 (7.0)2 (1.3)3 (1.1)0.008?Stroke, n (%)14 (2.2)6 (4.3)0 (0)5 (3.4)3 (1.1)0.071 Open in a separate window *Included percutaneous coronary intervention and coronary artery bypass grafting. MACE C major adverse cardiac events; NYHA C New York Heart Association. Supplementary Table 3 Multivariate COX analysis of Ralinepag ischemia-driven revascularization according to risk category of always beta-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”center” colspan=”1″ Ischemia-driven revascularization# /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.000.55 (0.26C1.15)0.48 (0.26C0.87)0.26 (0.14C0.47)? em P /em * value0.1140.016 0.001Model 2b?HR* (95% CI)1.000.56 (0.26C1.18)0.48 (0.26C0.88)0.26 (0.15C0.48)? em P /em * value0.1280.017 0.001Model 3c?HR* (95% CI)1.000.55 (0.26C1.16)0.45 (0.24C0.83)0.25 (0.14C0.46)? em P /em * value0.1150.010 0.001Model 4d?HR* (95% CI)1.000.46 (0.22C0.99)0.29 (0.15C0.54)0.14 (0.08C0.26)? em P /em * value0.047 0.001 0.001 Open in a separate window *Compared with the no therapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of ACEI or ARB, revascularization at baseline; #included percutaneous coronary intervention and coronary artery bypass grafting. There were 0 cardiovascular death, 8 myocardial infarction, and 14 stroke during the follow-up. The incidence of cardiovascular death, myocardial infarction, and stroke were low and did not allow for further analysis. CI C confidence interval; HR C hazard ratio. Supplementary Table 4 Multivariate COX analysis of progress to NYHA III or IV according to risk category of always b-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”center” colspan=”1″ Progress to NYHA III or IV /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th.The incidence of cardiovascular death, MI, and stroke was low and did not allow for further analysis (Supplementary Tables 3, 4). Subgroup analysis We also conducted a subgroup analysis between groups. fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline. Furthermore, relative to the no therapy group, the statin monotherapy group and the cotherapy group showed a lower risk of ischemia-driven revascularization and cardiac function NYHA III or IV progression. There were no cardiovascular deaths, 8 MIs, and 14 strokes during the follow-up. The incidence of cardiovascular death, MI, and stroke was low and did not allow for further analysis (Supplementary Tables 3, 4). Subgroup analysis We also conducted a subgroup analysis between groups. In the univariate Cox regression model (Model 1), the cotherapy group showed a lower MACE occurrence than the beta-blocker monotherapy group (HR 0.39, 95% CI 0.20C0.76, Cotherapy*Cotherapy**values are based on comparison with beta-blocker monotherapy group; **HR and values are based on comparison with statin monotherapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline. In addition, relative to the statin monotherapy group, the cotherapy group showed a significant 49% reduction in MACE occurrence (HR 0.51, 95% CI 0.28C0.92, value /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=636 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead MACE98 (15.4)40 (28.8)14 (19.7)22 (14.8)22 (7.9) 0.001?Cardiovascular death, n (%)0 (0)0 (0)0 (0)0 (0)0 (0)C?Myocardial infarction, n (%)8 (1.3)1 (0.7)2 (2.8)1 (0.7)4 (1.4)0.531?Ischemia-driven revascularization*, n (%)73 (11.5)31 (22.3)9 (12.7)16 (10.7)17 (6.1) 0.001?Progress to NYHA III or IV, n (%)17 (2.7)7 (5.0)5 (7.0)2 (1.3)3 (1.1)0.008?Stroke, n (%)14 (2.2)6 (4.3)0 (0)5 (3.4)3 (1.1)0.071 Open in a separate window *Included percutaneous coronary intervention and coronary artery bypass grafting. MACE C major adverse cardiac events; NYHA C New York Heart Association. Supplementary Table 3 Multivariate COX analysis of ischemia-driven revascularization relating to risk category of constantly beta-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”center” colspan=”1″ Ischemia-driven revascularization# /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.000.55 (0.26C1.15)0.48 (0.26C0.87)0.26 (0.14C0.47)? em P /em * value0.1140.016 0.001Model 2b?HR* (95% CI)1.000.56 (0.26C1.18)0.48 (0.26C0.88)0.26 (0.15C0.48)? em P /em * value0.1280.017 0.001Model 3c?HR* (95% CI)1.000.55 (0.26C1.16)0.45 (0.24C0.83)0.25 (0.14C0.46)? em P /em * value0.1150.010 0.001Model 4d?HR* (95% CI)1.000.46 (0.22C0.99)0.29 (0.15C0.54)0.14 (0.08C0.26)? em P /em * value0.047 0.001 0.001 Open in a separate window *Compared with the no therapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, older myocardial infarction, atrial fibrillation; dModel 4: Ralinepag Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, older myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of ACEI or ARB, revascularization at baseline; #included percutaneous coronary treatment and coronary artery bypass grafting. There were 0 cardiovascular death, 8 myocardial infarction, and 14 stroke during the follow-up. The incidence of cardiovascular death, myocardial infarction, and stroke were low and did not allow for further analysis. CI C confidence interval; HR C risk ratio. Supplementary Table 4 Multivariate COX analysis of progress to NYHA III or IV relating to risk category of constantly b-blocker and statin treatment. thead th valign=”middle” rowspan=”2″ align=”center” colspan=”1″ Progress to NYHA III or IV /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ No therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ beta-Blocker mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Statin mono-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ Co-therapy /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=139 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=71 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=149 /th th valign=”middle” align=”center” rowspan=”1″ colspan=”1″ n=277 /th /thead Model 1a?HR* (95% CI)1.001.36 (0.43C4.30)0.26 (0.06C1.27)0.21 (0.05C0.80)? em P /em * value0.5980.0970.023Model 2b?HR* (95% CI)1.001.18 (0.37C3.77)0.25 (0.05C1.21)0.20 (0.05C0.76)? em P /em * value0.7850.0850.018Model 3c?HR* (95% CI)1.001.05 (0.32C3.38)0.24 (0.05C1.18)0.17 (0.04C0.65)? em P /em * value0.9420.0800.010Model 4d?HR* (95% CI)1.001.04 (0.32C3.38)0.24 (0.05C1.23)0.17 (0.04C0.68)? em P /em * value0.9520.0880.013 Open in a separate window *Compared with the no therapy group; aModel 1: Unadjusted; bModel 2: Multivariate adjustment was made for age, sex, smoking, body mass index; cModel 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, older myocardial infarction, atrial fibrillation; dModel 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, older myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of ACEI or ARB, revascularization at baseline. There were 0 cardiovascular death, 8 myocardial infarction, and 14 stroke during the follow-up. The incidence of cardiovascular death,.
